FirstWord Publishing, Dec 2009, Pages: 48
Challenges for Biobetters
- The Challenge of MarketingBiobetterDrugs
- Pricing and Reimbursement
- Possible Increasing Biosimilar Competition
- Biosimilar Price Reductions
Opinions of Thought Leaders
Just Pharma Reports, March 2012, Pages: 135
Opportunities
Insulins
Interferon alfa
Monoclonal antibodies
Orphan drugs
10. Future Biosimilar Market Opportunities
Europe
US
Japan
Korea
Emergingmarkets
11. Biosimilar Challenges
Intellectual
FirstWord Publishing, Nov 2011, Pages: 47
are there to be learned?
Report Overview
In BiosimilarDrugs in Europe: Threat or Opportunity to Innovation?, FirstWord Dossier examines the emergingbiosimilars market. The report, based on expert interviews
Decision Resources, Inc., March 2011, Pages: 42
for MAbs, black box warnings on 18 MAb labels, premium pricing, market entry of biosimilars, prospects for biobetters, emergingmarkets, dealmaking, contingency payments.
- Primary data: Data from a survey
Decision Resources, Inc., March 2011, Pages: 32
, (2) exploring biobetteropportunities, (3) further penetrating emergingmarkets with protein therapy brands, (4) exploring biosimilaropportunities, and (5) investigating opportunities for rare-disease
Biophoenix Limited, July 2009, Pages: 275
Biosimilars and Biobetters: Positioning for a New Market As regulatory frameworks for biosimilars development begin to take shape worldwide, there are growing opportunities for generics companies
Decision Resources, Inc., Oct 2011
biologics markets. What are biobetters? What technological advances exist for designing new and improved recombinant protein and MAb therapies?
- Rare diseases have emerged as an attractive drug development
Datamonitor, Aug 2011, Pages: 40
Sciences developed first-generation biosimilarsmarketed in Europe
Hanwha Chemical signed a major, global deal with Merck in
Hanall BioPharma is focusing on the US market and biobetters
South
Decision Resources, Inc., Nov 2011
of prescription drug sales, nontraditional players.
Business opportunities: Life-cycle management, innovative R&D, established products, hybrid business model, branded generics, emergingmarkets, Japanese generics
Arena-International, March 2010
-- Anjan Selz, CEO, Finox
Evaluating the market landscape for biosimilars in emergingmarkets to establish threats and opportunities with focus on Latin America
-- Dr. Paulo Junqueira, Medical Leader
GBI Research, April 2012, Pages: 70
Growth Strategies for Supergenerics Organizations - Opportunities in Addressing Unmet Medical Needs and Providing Cost-Effective Solutions for Product Development in EmergingMarkets GBI
UBM Canon, Aug 2010, Pages: 70
will likely follow the lead of the biotech industry toward the production of biosimilar and biobetter vaccines. India and China are emerging as competitors in this area. Both countries have exhibited great
Business Insights, Feb 2010, Pages: 146
analytical testing and method development, as GMP (Good Manufacturing Practice) APIs in clinical trials, and as source materials for manufacturing marketeddrugs.
Sourcing APIs from low-cost suppliers
Taiyou Research, June 2011, Pages: 430
. Challenges related to regulations, investment, public support, amongst others are analyzed comprehensively.
- The emergence and growing importance of biosimilars is looked at with regards to the importance
